Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094665 | 0.90 | CYP3A4 (0.42) | CYP2C9KCNH2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL3398507 | 0.90 | CYP2C9 (0.44) | CYP2C9KCNH2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL4093302 | 0.89 | CYP2C9 (0.43) | CYP2C9KCNH2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL3398826 | 0.86 | CYP2C9 (0.54) | CYP2C9KCNH2CYP3A4CYP2C19 | |
| SCHEMBL16494216 | 0.86 | PTGS2 (0.36) | CYP2C9KCNH2CYP3A4CYP2C19 | |
| SCHEMBL2840204 | 0.84 | CYP2C9 (0.46) | CYP2C9KCNH2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL2842699 | 0.84 | CYP2C9 (0.46) | CYP2C9KCNH2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL2843902 | 0.83 | CYP2C9 (0.47) | CYP2C9KCNH2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL14323627 | 0.83 | CYP2C9 (0.45) | CYP2C9KCNH2CYP3A4CYP2C19CACNA1C | |
| SCHEMBL2834892 | 0.82 | CYP3A4 (0.43) | CYP2C9KCNH2CYP3A4CYP2C19CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245023-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2011-12-28 | — | — | EP | claimed |
| US-8071797-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-12-06 | — | — | US | claimed |
| EP-2245023-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | claimed |
| WO-2009101022-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | WO | claimed |
| US-20090208449-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2009-08-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208449-A1 | Heterocyclic antiviral compounds | EIF2AK2, HCCS, RTF2 | CYP2C9 416/4885KCNH2 3446/4885CYP3A4 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.